HCPLive Network

Despite Combined Antiretroviral Treatment, Anal Cancer Risk Still High for HIV-Infected

 
THURSDAY, Dec. 13 (HealthDay News) -- For HIV-infected patients, despite combined antiretroviral treatment (cART), the risk of anal cancer is still much higher than in the general population, according to a study published in the Dec. 10 issue of the Journal of Clinical Oncology.

Christophe Piketty, M.D., Ph.D., from the Hôpital Européen Georges Pompidou in Paris, and colleagues compared the incidence rates of anal cancer across four time periods: 1992 to 1996 (pre-cART); 1997 to 2000 (early cART); and 2001 to 2004 and 2005 to 2008 (both recent cART). During these periods, 263 cases of histologically confirmed invasive anal squamous cell carcinoma were identified.

The researchers found that, for HIV-infected patients, the hazard ratio for anal cancer was 2.5 in the cART periods versus the pre-cART period, with no difference noted across the cART calendar periods. In 2005 to 2008, compared with the general population, for HIV-infected patients there was an excess risk of anal cancer with a standardized incidence ratio of 109.8 for men who have sex with men (MSM), 49.2 for other men, and 13.1 for women. For patients with CD4 counts above 500/µL for at least two years, the standardized incidence ratios were 67.5 and 24.5, respectively, when the CD4 nadir was less than 200/µL for more than two years or more than 200/µL.

"Relative to that in the general population, the risk of anal cancer in HIV-infected patients is still extremely high, even in patients with high current CD4 cell counts," the authors write. "cART appears to have no preventive effect on anal cancer, particularly in MSM."
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 

Further Reading
Micronutrient supplementation reduces the risk of immune decline and morbidity in adults with early-stage HIV disease who have not yet initiated antiretroviral therapy, according to research published in the Nov. 27 issue of the Journal of the American Medical Association.
Early in the course of primary HIV-1 infection, a 48-week session of antiretroviral therapy (ART) delays disease progression versus no ART; and initiation of ART more than four months after the estimated start date of HIV infection reduces the likelihood of CD4+ T-cell count recovery, according to two studies published in the Jan. 17 issue of the New England Journal of Medicine.
For uninfected partners of HIV-positive individuals in China, transmission is reduced with antiretroviral therapy for the HIV-positive individual, according to a study published online Dec. 1 in The Lancet.
The use of first-line, generic-based antiretroviral HIV treatment in the United States could potentially save almost $1 billion in the first year of implementation, according to a study published in the Jan. 15 issue of the Annals of Internal Medicine.
Life expectancy among HIV-positive adults in the United States and Canada treated with combination antiretroviral therapy has greatly improved since 2000, with 20-year-olds now expected to live into their 70s, according to a study published online Dec. 18 in PLOS ONE.
Researchers report that efavirenz may produce a potent neurotoxic effect that may contribute to neurocognitive decline in HIV-infected patients who take the drug long-term.
Researchers look to determine why young HIV patients exhibit illnesses commonly associated with older people, despite all the progress that has been made.
More Reading